Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 131-141

  Chou, Jeffrey ^a   Voong, Lilien N ^b   Mortales, Christie L ^a   Towlerton, Andrea M H ^a   Pollack, Seth M ^a   Chen, Xiaoji ^a   Yee, Cassian ^a   Robbins, Paul F ^c   Warren, Edus H ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer testis antigens; colorectal cancer; cytolytic T lymphocyte; NY ESO 1; real time cell electrical sensing assay

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; NY ESO 1 ANTIGEN; POLYCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; FIBROBLAST; HISTOCOMPATIBILITY COMPLEX; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC ORGANISM; TUMOR GENE;

ANIMALS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CANCER VACCINES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863138984     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31824300c7     Document Type: Article

References (57)

1. Boyle P, Levin B. World Cancer Report 2008. Lyon: IARC Press; 2008.
2. Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer followup period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br J Cancer. 2004;91: 1711-1717. (Pubitemid 39546145)
3. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494. (Pubitemid 28376536)
4. Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab Invest. 2004;84:493-501. (Pubitemid 41656477)
5. Phillips SM, Banerjea A, Feakins R, et al. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg. 2004;91:469-475. (Pubitemid 38491119)
6. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244: 986-992; discussion 992-993. (Pubitemid 44808640)
7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. (Pubitemid 44498003)
8. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666. (Pubitemid 41817714)
9. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologicbased prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610-618.
10. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-1166. (Pubitemid 24249302)
11. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168-16173. (Pubitemid 35462767)
12. Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24:5060-5069. (Pubitemid 46631410)
13. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;32:5233-5239.
14. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358:2698-2703. (Pubitemid 351860862)
15. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.
16. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5:615-625. (Pubitemid 41081387)
17. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002;62:4041-4047. (Pubitemid 34791072)
18. Li M, Yuan YH, Han Y, et al. Expression profile of cancertestis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 2005;11:1809-1814. (Pubitemid 40471843)
19. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: Review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30. (Pubitemid 44088423)
20. Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-aza-20-deoxycytidine activates NYESO- 1 antigenicity in orthotopic human glioma. Int J Cancer. 2008;122:2542-2553. (Pubitemid 351590488)
21. Coral S, Sigalotti L, Altomonte M, et al. 5-aza-20-deoxycytidine- induced expression of functional cancer testis antigens in human renal cell carcinoma: Immunotherapeutic implications. Clin Cancer Res. 2002;8:2690-2695. (Pubitemid 34856358)
22. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24:151-161. (Pubitemid 32183061)
23. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-20-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 2009;58:589-601.
24. Wargo JA, Robbins PF, Li Y, et al. Recognition of NY-ESO- 1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother. 2009;58:383-394.
25. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene. 2006;25:6975-6985. (Pubitemid 44684838)
26. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129. (Pubitemid 44547756)
27. Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005;174:4415-4423. (Pubitemid 40396025)
28. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180:6116-6131.
29. Tykodi SS, Fujii N, Vigneron N, et al. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res. 2008;14:5260-5269.
30. Riddell SR, Greenberg PD. The use of anti-CD3 and anti- CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201. (Pubitemid 20120262)
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408. (Pubitemid 34164012)
32. King JY, Ferrara R, Tabibiazar R, et al. Pathway analysis of coronary atherosclerosis. Physiol Genomics. 2005;23:103-118.
33. Vaughan HA, Svobodova S, Macgregor D, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 2004;10:8396-8404. (Pubitemid 40053402)
34. Barbany G, Hagberg A, Olsson-Stromberg U, et al. Manifoldassisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem. 2000;46:913-920. (Pubitemid 30461260)
35. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187:1349-1354. (Pubitemid 28189124)
36. Kreso A, O'Brien CA. Colon cancer stem cells. Curr Protoc Stem Cell Biol. 2008. Chapter 3:Unit 3.1.1-3.1.12.
37. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000;165:948-955. (Pubitemid 30484763)
38. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998; 187:265-270. (Pubitemid 28060443)
39. Rimoldi D, Rubio-Godoy V, Dutoit V, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000;165:7253-7261. (Pubitemid 32001204)
40. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51-64. (Pubitemid 35398865)
41. Shim E, Shim H, Bae J, et al. CAGE displays oncogenic potential and induces cytolytic T lymphocyte activity. Biotechnol Lett. 2006;28:515-522.
42. Ayyoub M, Merlo A, Hesdorffer CS, et al. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol. 2005;114:70-78. (Pubitemid 39642792)
43. Adair SJ, Carr TM, Fink MJ, et al. The TAG family of cancer/ testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 31 7-17. (Pubitemid 351619399)
44. Oehlrich N, Devitt G, Linnebacher M, et al. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005;117:256-264. (Pubitemid 41377446)
45. Godefroy E, Wang Y, Souleimanian NE, et al. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunol Immunother. 2007; 56:1183-1192. (Pubitemid 46763933)
46. Ayyoub M, Stevanovic S, Sahin U, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumorreactive CTL infiltrating metastatic melanoma. J Immunol. 2002;168:1717-1722. (Pubitemid 34135769)
47. Ma W, Germeau C, Vigneron N, et al. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer. 2004;109:698-702. (Pubitemid 38405616)
48. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J. 2008;22:659-661. (Pubitemid 351348146)
49. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620-626.
50. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135: 1079-1099.
51. Rashid A, Shen L, Morris JS, et al. CpG island methylation in colorectal adenomas. Am J Pathol. 2001;159:1129-1135. (Pubitemid 32847204)
52. Hinoue T, Weisenberger DJ, Pan F, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One. 2009;4:e8357.
53. Yawata T, Nakai E, Park KC, et al. Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog. 2010;49:532-544.
54. Brunner KT, Mauel J, Cerottini JC, et al. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968;14:181-196.
55. Zhu J,Wang X, Xu X, et al. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods. 2006;309:25-33. (Pubitemid 43190799)
56. Glamann J, Hansen AJ. Dynamic detection of natural killer cellmediated cytotoxicity and cell adhesion by electrical impedance measurements. Assay Drug Dev Technol. 2006;4:555-563. (Pubitemid 46017399)
57. Solly K, Wang X, Xu X, et al. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol. 2004;2:363-372. (Pubitemid 39276278)